Spruce Biosciences Bolsters Leadership Ahead of Key Regulatory Milestones

Event summary

  • Spruce Biosciences appointed Daven Mody as Senior Vice President of Regulatory and Quality and Bruno Gagnon as Senior Vice President, Clinical Development Operations on February 3, 2026.
  • Both executives received inducement awards of 5,500 restricted stock units (RSUs) each, vesting over four years.
  • Mody brings 25 years of regulatory experience, including roles at Theravance Biopharma and Impax Laboratories.
  • Gagnon has over 30 years of clinical operations experience, previously leading programs at BioMarin and BridgeBio Pharma.

The big picture

Spruce Biosciences is strengthening its leadership team ahead of critical regulatory milestones for its tralesinidase alfa program. The appointments of Mody and Gagnon signal a focus on streamlining regulatory pathways and optimizing clinical trial execution, which are crucial for securing FDA approval and advancing other pipeline programs. This move aligns with broader industry trends of biopharmaceutical companies bolstering their regulatory and clinical operations capabilities to navigate complex approval processes for rare disease treatments.

What we're watching

Regulatory Execution
How Mody's experience with NDAs and MAAs will impact Spruce's BLA submission for tralesinidase alfa.
Clinical Trial Pace
Whether Gagnon can accelerate the confirmatory study of TA-ERT and other pipeline programs.
Leadership Integration
The effectiveness of the new leadership team in driving Spruce's strategic objectives during this transformative period.